Zura Bio Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ZURA Nasdaq 2830 zurabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zura Bio Limited

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 21st, 2026 5:57 pm
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - Aug 11th, 2026 5:30 am
William Blair Starts Zura Bio (ZURA) at Outperform - Jul 14th, 2026 12:09 pm
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program - Jun 29th, 2026 5:30 am
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Jun 3rd, 2026 4:09 am
One Zura Bio Insider Raised Their Stake In The Previous Year - Apr 23rd, 2026 4:06 am
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - Feb 25th, 2026 1:26 pm
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - Feb 25th, 2026 1:19 pm
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - Feb 25th, 2026 1:11 pm